These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18521794)

  • 1. [Oncology 2008].
    Stemmler HJ; Heinemann V
    Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1395-9. PubMed ID: 18521794
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch; Budak K; Pestalozzi B
    Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges and pitfalls of combining targeted agents in phase I studies.
    Cannistra SA
    J Clin Oncol; 2008 Aug; 26(22):3665-7. PubMed ID: 18669449
    [No Abstract]   [Full Text] [Related]  

  • 4. [Targeted therapy for metastatic bladder cancer].
    Vom Dorp F; Börgermann C; Rose A; Becker M; Rübben H
    Urologe A; 2008 Oct; 47(10):1311-4. PubMed ID: 18587555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
    Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
    [No Abstract]   [Full Text] [Related]  

  • 6. [Targeted therapies and their indications in solid neoplasias].
    Dreyer C; Raymond E; Faivre S
    Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
    Hanna N
    J Thorac Oncol; 2006 Nov; 1(9):927-8. PubMed ID: 17409973
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
    Marsh AM; Lo L; Cohen RA; Feusner JH
    Pediatr Blood Cancer; 2012 Nov; 59(5):939-40. PubMed ID: 22492703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular therapy of pancreatic cancer.
    Plentz RR; Manns MP; Greten TF
    Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising systemic therapy for renal cell carcinoma.
    Cooney MM; Remick SC; Vogelzang NJ
    Curr Treat Options Oncol; 2005 Sep; 6(5):357-65. PubMed ID: 16107239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents for the treatment of advanced kidney cancer.
    Cooney MM; Remick SC; Vogelzang NJ
    Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
    Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma.
    Launay-Vacher V; Ayllon J; Janus N; Medioni J; Deray G; Isnard-Bagnis C; Oudard S
    Urol Oncol; 2011; 29(5):492-4. PubMed ID: 19914102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of clinical trials of radiation combined with antiangiogenic therapy.
    Senan S; Smit EF
    Oncologist; 2007 Apr; 12(4):465-77. PubMed ID: 17470689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
    Waidmann O; Hofmann WP; Zeuzem S; Trojan J
    J Hepatol; 2011 Feb; 54(2):396-8. PubMed ID: 21111506
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
    Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
    J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting angiogenesis in bladder cancer.
    Elfiky AA; Rosenberg JE
    Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.